Overview

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, exploratory clinical study
Phase:
PHASE4
Details
Lead Sponsor:
Jiangsu Famous Medical Technology Co., Ltd.
Treatments:
dalpiciclib